Skip to content

Efficacy and Safety of Green-Lipped Mussel Powder Supplementation in Adults with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Green-Lipped Mussel Powder Supplementation in Adults with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0008821
Enrollment
100
Registered
2023-09-22
Start date
2023-10-31
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : - Green-lipped mussel powder 1,000 mg/day(500 mg x 2 capsules) - oral intake with water once a day after breakfast or dinner - intake period: total 84 days(12 weeks) - Maltodext

Sponsors

Pusan National University Korean Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult men and women between the ages of 40 and 75 2. Those with a knee joint pain score (Visual Analogue Scale (VAS)) of 3/10 or higher 3. Those who are grade 1 or 2 on the Kellgren & Lawrence grading scale through ‘Both Knee Joint AP/LAT’ 4. Those who have had a wash-out period of arthritis-related medicines or health functional foods for more than 4 weeks 5. Applicants who are capable of normal physical activity are subjects of this test and voluntarily agree in writing to the test consent form

Exclusion criteria

Exclusion criteria: 1. Those with a history of fracture within the last year 2. Those who are diagnosed with moderate arthritis and are accompanied by osteophytes around the joints, irregular joint surfaces, and subchondral bone cysts of the joints. 3. Those diagnosed with thyroid disease and currently receiving treatment 4. Those with kidney disease or serum creatinine level of 1.4 mg/dL or higher 5. Those with proteinuria of 2+ or more 6. Those with liver disease (excluding fatty liver) or AST or ALT of 100 IU/L or more 7. Patients with uncontrolled high blood pressure or heart diseases such as angina pectoris or myocardial infarction 8. Persons taking medication for psychiatric illness (excluding cases of intermittent medication due to sleep disorders) 9. Those who have taken any herbal medicine or herbal medicine within 2 months before the screening test 10. Those who received other investigational drugs within 4 weeks before the screening test 11. Persons who must continue to take drugs that are judged to have an effect on the results of human application tests 12. Those with a history of gastrointestinal resection (excluding the appendix) 13. Pregnant or lactating women 14. Alcohol abuse 15. Persons with hypersensitivity to the test food or its ingredients 16. Persons who may be uncooperative in this examination Or a person who the researcher determines is unable to proceed with the test. 17. A person who, at the discretion of the test director, has arthritis caused by a specific factor other than degenerative disease.

Design outcomes

Primary

MeasureTime frame
WOMAC questionnaire total score

Secondary

MeasureTime frame
WOMAC questionnaire detailed item scores (pain, joint stiffness, physical function);Visual Analogue Scale;ESR(Erythrocyte Sedimentation Rate);CRP(C-reactive protein) density

Countries

Korea, Republic of

Contacts

Public ContactHyejin Park

Pusan National University Korean Medicine Hospital

hpark0214@gmail.com+82-55-360-5725

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Jul 18, 2026